This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
However, between 2013 and 2023, private equity firms made over 1,000 acquisitions of disability and elder care providers — a likely undercount, according to the report published by the Private Equity Stakeholder Project, a nonprofit watchdog focused on the growing impact of the private equity industry.
Work by device manufacturers to improve the performance of pulse oximeters on people with darker skin has progressed little since the Food and Drug Administration asked manufacturers in 2013 to voluntarily test the devices on more diverse skin tones, according to a study published Monday in JAMA.
of women aged 18-59 in 2013-2014. According to the CDC, HPV is the most commonly sexually transmitted infection in the US, with a prevalence of 45.2% of men and 39.9%
The study finds that since curative direct-acting antiviral medications for hepatitis C were approved in 2013, even after factoring in the cost of treatment, Medicaid has saved an estimated $15 billion in avoided health care costs and nearly 285,000 Medicaid enrollees are estimated to have been cured.
Joung, an early pioneer of the gene-editing technology, was the first to show CRISPR could target and cut DNA inside an embryo — in zebrafish — back in 2013. If, of course, society decided that was a good idea.
The lawsuit alleged that, since October 2013, CVS knowingly filled prescriptions for “dangerous and excessive quantities” of controlled substances that lacked a legitimate medical purpose, were not valid, and were not issued in the “usual course of professional practice. Department of Justice.
Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years
in 2013 to 19.3% The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% to 49.9%.
This was back in 2013, when such accommodations were a rarity. Even though Erin Booth was not thrilled about having to travel to Philadelphia for a conference at six weeks postpartum, this one at least advertised having a private lactation space.
Bik first became interested in plagiarism as a hobby while working as a researcher at Stanford University in 2013. She later began specializing in image duplication specifically, which she believes is a more serious problem for science as a whole. Read the rest…
billion was raised by 183 new VC funds, which was the lowest fundraising total for first-timers since 2013, according to Pitchbook. First-time funds have been difficult to raise during the biotech downturn. Last year, around $11.6 Around $25.6 billion had been raised by 556 first-time funds in 2022.
The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased cells, and use that data to identify drugs gathering dust on pharmaceutical company shelves that could be repurposed as rare disease treatments.
The first time I saw Maya (not her real name) huddled under blankets in a hospital bed in 2013, she had been to dozens of inpatient detox programs and residential treatment centers since she had begun using heroin two decades earlier. After every release, she returned to heroin use, usually within days.
Healthcare technology company Commure plans to buy Augmedix, a healthcare artificial intelligence company founded in 2013, the companies announced Friday. | On Friday, ambient AI documentation company Augmedix announced it had been bought by Commure, a large IT vendor to healthcare systems. The deal values the company at $139 million.
It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists , published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9.
Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found. One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials.
In 2013, it took an average of 9.9 In some cases, failure to show clinical benefit didn’t stop the FDA from converting accelerated approvals into full approvals, and the authors note the agency’s conversion decisions have increasingly been based on less stringent evidence of a drug’s benefits.
So far this year, there have been 1,384 VC deals struck in the field, the lowest figure since 2013. New data from Pitchbook and the National Venture Capital Association show that both the number of deals and the amount of money that’s being invested in life science companies are down significantly.
From 2013 to 2022, pharmaceutical and device companies made more than 85 million payments totaling $12.1 The financial ties between drug and device makers and some physicians remains pervasive, despite concerns such relationships may influence medical practice, according to a new analysis of payments made over a recent 10-year span.
AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July.
It’s hard to believe that I have been following pharmacist board certifications and helping pharmacists pass the BCPS exam for over 10 years since I first passed it in 2013! Each year in updating and creating our study materials, I review the content outline and any possible changes in the BCPS exam.
Founded in 2013, Pear was the most prominent company developing prescription digital therapeutics, or Food and Drug Administration-cleared software applications ordered by doctors to treat health conditions. Click Therapeutics, Welt Corp, Harvest Bio, and Nox Health Group each acquired bits of the company for $6.05
Over the past decade, the number of research misconduct allegations reported to the National Institutes of Health has more than doubled, climbing from 74 in 2013 to 169 in 2022. And it’s hardly alone. And scientific sleuths are finding plenty of other problems that don’t always qualify as outright misconduct.
Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics were all started in the 2013-2014 time frame with the same goal of turning the nascent CRISPR gene-editing technology into medicines.
Recent big pharma ABPI members While Novo Nordisk became a member of the APBI in 2013, other additions in recent years include Moderna, who gained membership in January 2023 , and Gilead, who joined the ABPI in January 2022. The post Novo Nordisk industry membership reinstated appeared first on European Pharmaceutical Review.
He has been part of the C-suite at Sage Therapeutics since 2013. Longtime Sage Therapeutics executive Jeff Jonas is leaving the biotech company to launch a biotech incubator with global investment giant CBC Group. Sage announced this week that Jonas would leave the company to join a private equity firm. billion deal with Biogen.
For example, the share of Mexican Americans taking insulin who achieved good blood-sugar control sharply dropped to 10% during the period of 2013 to 2020 from 25% during 1988 to 1994, researchers reported Tuesday in JAMA Network Open. Read the rest…
In 2013, I sat down at my computer and secured the URL t1international.com. I wanted a place where I could collect and share everything I was learning about the global insulin price crisis. I was only 25 years old, and I had already been living with type 1 diabetes for more than two decades.
The company, which last month pleaded guilty to a misdemeanor, admitted that, from April 2012 through May 2013, some of its sales representatives marketed its medicine, also known as oxymorphone, to doctors by touting the drug as abuse deterrent, as well as resistant to tampering and crushing.
It says the price increases were imposed “as though a new version of Acthar came on the market in 2013, when in fact, it did not,” which allowed it to ignore all price increases prior to 2013 in its rebate calculations.
After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis. |
Richard Gonzalez will retire as the company’s CEO to become Executive Chairman, having served as the company’s CEO since its launch in 2013, AbbVie noted. Richard has facilitated AbbVie securing a market capitalisation increase from $54 billion in 2013 to over $300 billion in 2024.
million from 2013 to 2019, presumably due to the company payments, according to the study, which was published in JAMA Health Forum. Physicians who did not accept payments prescribed Avastin 46% of the time, nearly twice as often as those who accepted payments. As a result, Medicare shelled out an estimated $642.8
Case in point: Under the seemingly benign title, “Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval,” an article published recently in the Journal of the American Medical Association claims that among “cancer drugs granted accelerated approval from 2013 to 2017, 41% (19/46) did not improve (..)
The study reviewed all 80 European Medicines Agency (EMA) authorised drugs receiving an orphan designation between 1 January 2013 and 31 December 2019, analysing their HTA outcomes and time to reimbursement across France, Germany, England and Scotland. Rates of approval. A more favourable outcome from the German regulator took on average 1.4
San Francisco-based Carbon said that Elevance — formerly known as Anthem, which operates the Anthem Blue Cross plan in California — had refused to increase its payment rate in the state beyond 2013 levels, which was “no longer tenable as a livable wage.” ” Continue to STAT+ to read the full story…
A federal law that went into effect in 2013 requires the FDA to identify ingredients needed to satisfy an unmet “clinical need” and to include those on a list for use by large compounding pharmacies.
When it hit the market in 2013, the drug revolutionized the treatment of these cancers and represented a major step forward from chemotherapy and some other drugs at the time. NEW ORLEANS – One of the best therapies for some types of lymphoma and leukemia has been a drug called ibrutinib, made by AbbVie.
In the spring of 2013, I had just visited a lab focused on gene and cell therapies at Baylor College of Medicine. Bluebird Bio , which would soon launch a successful IPO , had licensed its technology from the same lab and was about to announce a major collaboration with Celgene and Baylor.
Central Texas’ Scott and White was absorbed into Baylor in 2013. Wisconsin’s Marshfield Clinic agreed to merge with Duluth-based Essentia Health in October 2022 after a lengthy string of operating losses, though the merger fell apart recently.
Hospitals ran short of essential treatment medications and were unable to source those drugs from manufacturers or from the outsourcing facilities that had been authorized by Congress in 2013 to “fill the gap” in such situations.
The report from Berkeley Research Group (BRG) – which was funded by the pharma industry trade group PhRMA – reveals a steady decrease in the proportion received by drugmakers from around 67% in 2013 to 49.5%
based company was founded in 2013 and has raised $60 million to date. Perekupka said Freespira hopes to enroll 2,500 people in its treatment this year — twice last year’s sales — and to double its patients again in 2025 and 2026. The Kirkland, Wash.-based
are charged with knowingly selling defective lead testing machines between 2013 and 2017 that generated inaccurate results for tens of thousands of children across the country and for clients of at least one international relief organization, federal prosecutors said. Three former executives at Magellan Diagnostics Inc.
91
91
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content